

Advances in Lipid Research

Volume 17

Edited by

Rodolfo Paoletti David Kritchevsky



Advances in Lipid Research

Volume 17

Edited by

Rodolfo Paoletti

*Institute of Pharmacology
Milan, Italy*

David Kritchevsky

*The Wistar Institute
Philadelphia, Pennsylvania*



1980

ACADEMIC PRESS

A Subsidiary of Harcourt Brace Jovanovich, Publishers
New York London Toronto Sydney San Francisco

**COPYRIGHT © 1980, BY ACADEMIC PRESS, INC.
ALL RIGHTS RESERVED.**

**NO PART OF THIS PUBLICATION MAY BE REPRODUCED OR
TRANSMITTED IN ANY FORM OR BY ANY MEANS, ELECTRONIC
OR MECHANICAL, INCLUDING PHOTOCOPY, RECORDING, OR ANY
INFORMATION STORAGE AND RETRIEVAL SYSTEM, WITHOUT
PERMISSION IN WRITING FROM THE PUBLISHER.**

**ACADEMIC PRESS, INC.
111 Fifth Avenue, New York, New York 10003**

United Kingdom Edition published by
**ACADEMIC PRESS, INC. (LONDON) LTD.
24/28 Oval Road, London NW1 7DX**

LIBRARY OF CONGRESS CATALOG CARD NUMBER: 63-22330

ISBN 0-12-024917-0

PRINTED IN THE UNITED STATES OF AMERICA

80 81 82 83 9 8 7 6 5 4 3 2 1

PREFACE

One of the most intriguing current problems in the lipoprotein field, the metabolic role of high-density lipoproteins (HDL), is focused upon in the opening chapters of this volume. Almost 30 years ago Barr suggested that α -lipoprotein (HDL) levels played a possible predictive role in coronary heart disease. He hypothesized that a high α/β -lipoprotein ratio (HDL/LDL) predicted relative freedom from coronary disease and the converse predicted susceptibility. The role of HDL in cholesterol transport [as a component of the lecithin-cholesterol acyl transferase (or LCAT) system] was articulated by Glomset in the late 1960s and reviewed by him in this publication (1973). Other investigators have demonstrated that HDL actually transports cholesterol from cells. The role of HDL in cholesterol transport and HDL metabolism are the subjects of the first two chapters. The third chapter discusses cholesterol metabolism in various types of clinical hyperlipidemias, and addresses cholesterol turnover as a function of hypercholesterolemia, hypertriglyceridemia, or a combination of the two. Polyunsaturated fats are known to exert a hypocholesterolemic effect in man. The mechanism(s) underlying this observation is the subject of the fourth chapter.

Many lipids are susceptible to oxidation. Polyunsaturated fatty acids are the most readily oxidized, but even cholesterol is converted to oxidation products such as the 7- or 25-hydroxy derivatives. The topic of lipid peroxidation in mitochondrial membranes and its effects on alterations in cellular processes is discussed at length in the volume's fifth chapter. The final contribution also relates to membrane phenomena, but its thrust is toward the study of membrane structure by means of membrane-cooperative enzymes. The application of allosterism as a tool for membrane research also is explored.

RODOLFO PAOLETTI
DAVID KRITCHEVSKY

CONTENTS

| | |
|---------------------------|----|
| LIST OF CONTRIBUTORS..... | ix |
| PREFACE | xi |

Body Cholesterol Removal: Role of Plasma High-Density Lipoproteins

Alan R. Tall and Donald M. Small

| | |
|---|----|
| I. Introduction..... | 2 |
| II. Composition and Structure of High-Density Lipoproteins | 3 |
| III. Interaction of HDL with Phospholipid Bilayers and Membranes <i>in Vitro</i> | 19 |
| IV. HDL Metabolism | 26 |
| V. HDL in Health and Disease | 38 |
| References | 44 |

High-Density Lipoprotein Metabolism

A. Nicoll, N. E. Miller, and B. Lewis

| | |
|---|----|
| I. Composition, Structure, and Heterogeneity of HDL..... | 54 |
| II. Origin of HDL..... | 60 |
| III. HDL, LCAT, and Cholesterol Transport | 67 |
| IV. Relationship of HDL to Triglyceride Transport | 75 |
| V. Catabolism of HDL | 81 |
| VI. HDL Apoprotein Kinetics <i>in Vivo</i> | 85 |
| VII. Regulation of Plasma HDL Levels and Metabolism | 89 |
| References | 96 |

Cholesterol Metabolism in Clinical Hyperlipidemias

Harbhajan S. Sodhi, Bhalchandra J. Kudchodkar, and Dean T. Mason

| | |
|------------------------------|-----|
| I. Introduction | 107 |
| II. Analytical Methods | 109 |
| III. Results | 113 |
| IV. Discussion | 140 |
| References | 151 |

On the Mechanism of Hypocholesterolemic Effects of Polyunsaturated Lipids

Ranajit Paul, C. S. Ramesha, and J. Ganguly

| | |
|---|-----|
| I. Introduction | 155 |
| II. Hypocholesterolemic Agents | 156 |
| III. Effect of Dietary Lipids on Bile | 160 |
| IV. Effect of Dietary Lipids on Plasma Lipoproteins | 165 |
| V. Possible Overall Mechanism of Cholesterol Loss | 167 |
| VI. Polyunsaturated Lipids and Gallstone | 168 |
| VII. Summary | 169 |
| References | 170 |

Lipid Peroxidation in Mitochondrial Membrane

Yu. A. Vladimirov, V. I. Olenov, T. B. Suslova, and Z. P. Cheremisina

| | |
|---|-----|
| I. Introduction | 174 |
| II. Reaction Kinetics of Lipid Peroxidation in Mitochondrial Membranes | 175 |
| III. Control Mechanisms of Lipid Peroxidation | 205 |
| IV. Effect of Lipid Peroxidation on the Biological Membrane Structure and Function | 216 |
| V. Discussion of the Possible Role of Lipid Peroxidation in Cell Life and Development of Pathological Processes | 231 |
| VI. Conclusion | 240 |
| References | 241 |

Membrane Cooperative Enzymes as a Tool for the Investigation of Membrane Structure and Related Phenomena

Ricardo Norberto Farías

| | |
|--|-----|
| I. Introduction | 251 |
| II. Properties of Membrane-Bound Enzymes under Study | 252 |

5 Dn
P15

Contents

vii

| | |
|---|-----|
| III. Regulation of Membrane Cooperative Enzymes | 253 |
| IV. Application of Allosteric Probe for Membrane Research | 263 |
| References | 280 |
| Note Added in Proof | 282 |
| AUTHOR INDEX | 283 |
| SUBJECT INDEX | 301 |
| CONTENTS OF PREVIOUS VOLUMES | 305 |

1803

8442

82-5-6

067336

LIST OF CONTRIBUTORS

Numbers in parentheses indicate the pages on which the authors' contributions begin.

Z. P. CHEREMISINA, *Second Moscow State Medical Institute, Moscow, USSR* (173)

RICARDO NORBERTO FARIAS, *Instituto de Química Biológica, Facultad de Bioquímica, Química y Farmacia, San Miguel de Tucumán, 4000 Tucumán, Argentina* (251)

J. GANGULY, *Department of Biochemistry, Indian Institute of Science, Bangalore 560 012, India* (155)

BHALGHANDRA J. KUDCHODKAR,¹ *The Lipid Research Laboratory and Clinic, Section of Cardiovascular Medicine, Departments of Medicine and Physiology, University of California School of Medicine and Sacramento Medical Center, Davis and Sacramento, California* (107)

B. LEWIS, *Department of Chemical Pathology and Metabolic Disorders, St. Thomas' Hospital Medical School, London, England* (53)

DEAN T. MASON, *Departments of Medicine and Physiology, University of California School of Medicine and Sacramento Medical Center, Davis and Sacramento, California* (107)

N. E. MILLER, *Department of Chemical Pathology and Metabolic Disorders, St. Thomas' Hospital Medical School, London, England* (53)

A. NICOLL, *Department of Chemical Pathology and Metabolic Disorders, St. Thomas' Hospital Medical School, London, England* (53)

V. I. OLENEV, *Second Moscow State Medical Institute, Moscow, USSR* (173)

¹ Present address: Division of Endocrinology and Metabolism and Northwest Lipid Research Clinic, University of Washington, Seattle, Washington 98104.

RANAJIT PAUL,² *Department of Biochemistry, Indian Institute of Science, Bangalore 560 012, India (155)*

C. S. RAMESHA, *Department of Biochemistry, Indian Institute of Science, Bangalore 560 012, India (155)*

DONALD M. SMALL, *Biophysics Institute, Boston University Medical Center, Boston, Massachusetts 02118 (1)*

HARBHAJAN S. SODHI, *Department of Internal Medicine, Division of Cardiology, University of California School of Medicine and Sacramento Medical Center, Davis and Sacramento, California (107)*

T. B. SUSLOVA, *Second Moscow State Medical Institute, Moscow, USSR (173)*

ALAN R. TALL, *Department of Medicine, Columbia University College of Physicians and Surgeons, New York, New York 10032 (1)*

YU. A. VLADIMIROV, *Second Moscow State Medical Institute, Moscow, USSR (173)*

² Present address: Department of Microbiology, University of Virginia School of Medicine, Charlottesville, Virginia 22901.

Body Cholesterol Removal: Role of Plasma High-Density Lipoproteins¹

ALAN R. TALL

*Department of Medicine,
Columbia University College of Physicians and Surgeons
New York, New York*

DONALD M. SMALL

*Biophysics Institute,
Boston University Medical Center,
Boston, Massachusetts*

| | |
|--|----|
| I. Introduction | 2 |
| II. Composition and Structure of High-Density Lipoproteins..... | 3 |
| A. Composition | 3 |
| B. Apolipoprotein Structure..... | 4 |
| C. Recombinants of Apolipoproteins and Lipids..... | 7 |
| D. Structure of Bile Salt/Lecithin Mixed Micelles..... | 12 |
| E. Cholesterol in HDL Recombinants..... | 12 |
| F. Structure of Plasma HDL, HDL ₂ , and HDL ₃ | 14 |
| III. Interaction of HDL with Phospholipid Bilayers and Membranes <i>in Vitro</i> | 19 |
| A. Liposomes and Vesicles..... | 19 |
| B. Cells in Tissue Culture..... | 23 |
| IV. HDL Metabolism..... | 26 |
| A. Enzyme Activation..... | 26 |
| B. Sources of Plasma HDL: Secretory, Lipolytic..... | 27 |
| C. Possible Mechanism for Formation of HDL from VLDL or Chylomicrons | 32 |
| D. Turnover Studies..... | 34 |
| E. HDL in Lymph and Other Body Fluids..... | 36 |
| F. Removal of HDL..... | 36 |
| G. HDL and Cholesterol Balance..... | 37 |
| V. HDL in Health and Disease..... | 38 |
| A. HDL and Cardiovascular Disease..... | 38 |
| B. Conditions with Increased or Decreased HDL Levels..... | 39 |
| C. Tangier Disease..... | 41 |
| D. LCAT Deficiency..... | 42 |
| E. Accumulation of Vesicular Lipoproteins in Plasma..... | 43 |
| References..... | 44 |

Supported by National Health Service Grants HL 18673, HL 07291, and HL 22682, and a Grant-in-Aid from the American Heart Association (316-3070-2286).

I. Introduction

The human body is abundantly equipped with mechanisms for the provision and maintenance of tissue cholesterol levels. Cholesterol absorption increases with dietary intake, with no apparent upper limit (Borgstrom, 1968). In times of reduced intake the liver and small intestine increase their synthesis of cholesterol (Dietschy and Wilson, 1970; Grundy *et al.*, 1969; Dietschy and Gamel, 1971). Absorbed cholesterol is transported to the liver as chylomicron remnants (Redgrave, 1970; Nervi *et al.*, 1975; Andersen *et al.*, 1977) and hepatic cholesterol is either secreted as very low-density lipoproteins which are catabolized in part to low-density lipoproteins (Eisenberg and Levy, 1975), or secreted into bile as free cholesterol or its metabolites, the bile salts (Small *et al.*, 1972; Grundy *et al.*, 1974). LDL delivers cholesterol to the peripheral tissues, where specific cell surface receptors bind, internalize, and degrade the LDL particles, providing the cell with cholesterol (Brown and Goldstein, 1976; Goldstein and Brown, 1977). In the absence of an adequate supply of lipoprotein cholesterol, the cholesterol synthesis pathway is activated in peripheral tissues (Andersen and Dietschy, 1976).

Although a great deal is known about cholesterol synthesis and delivery, there is relatively little information about the role of a removal mechanism in the regulation of tissue cholesterol levels. That regulation is exerted by cholesterol removal involving plasma high-density lipoproteins has at this time the status of a good working hypothesis. The evidence can be summarized as follows:

1. In epidemiological studies plasma levels of HDL are correlated inversely with the incidence of atherosclerotic cardiovascular disease.

2. There is probably an inverse correlation between levels of HDL cholesterol and tissue cholesterol pools.

3. HDL and HDL-like particles can remove cholesterol from cells in tissue culture.

4. HDL is a preferred substrate for plasma lecithin:cholesterol acyltransferase, an enzyme which converts surface cholesterol into core cholesterol ester, thereby creating a gradient for transfer of membrane unesterified cholesterol into HDL.

This review will present our views of HDL structure and metabolism, particularly as it might be related to cholesterol homeostasis. Emphasis is placed on the composition and structure of HDL, the physical structure of the individual components of HDL, and the different HDL recombinants. These structural considerations are intimately related to the formation and

function of plasma HDL. Much of our discussion is based on *in vitro* or physiological experiments conducted with both human and nonhuman subject matter. Consequently, many of our conclusions are speculative and are intended as a starting point for further experimental testing. Comprehensive reviews of lipoprotein metabolism (Eisenberg and Levy, 1975) and structure (Scanu and Wisdom, 1972; Jackson *et al.*, 1976; Morrisett *et al.*, 1975; Smith *et al.*, 1978) have been published.

II. Composition and Structure of High-Density Lipoproteins

A. COMPOSITION

Human HDL is operationally defined as the class of lipoproteins isolated between densities 1.063–1.125 g/ml (HDL₂) and 1.125–1.21 g/ml (HDL₃) in the preparative ultracentrifuge. A minor component, HDL₁, has been isolated between density 1.050 and 1.063 g/ml. HDL₂ consists of ~ 40% apoprotein and 60% lipid and HDL₃ of 55% protein and 45% lipid. The lipids comprise 44% phospholipid, 6% cholesterol, 28% cholesteryl ester, and 16% triglyceride (Scanu and Wisdom, 1972). By sedimentation equilibrium the molecular weights of HDL₂ and HDL₃ are 320,000 and 175,000, respectively. (Scanu and Granda, 1966). Values of 360,000 and 184,000 have been obtained by small angle X-ray scattering studies.

The principal apoproteins include apoA-I (MW ~ 28,000), apoA-II (MW ~ 17,000) and the smaller C-apolipoproteins (MW 5000–8000). ApoA-I and apoA-II together comprise about 90% of the apoprotein. Other minor components that have been identified in human HDL include apoD (also called "thin-line" polypeptide; MW 22,100) (McConathy and Alaupovic, 1976), apoE (MW ~ 34,000; also known as the arginine-rich peptide), apoF (MW 26,000–32,000; Olafsson *et al.*, 1978), and two threonine-poor apoproteins (MW 40,000 and 10,000; Shore *et al.*, 1978). A subfraction of human HDL₂ contains an apoprotein of MW 48,000 termed "pro-arginine rich" apoprotein, because on disulfide reduction it dissociates into two subunits one of which appears to be the arginine-rich apoprotein and the other apoA-II (Weisgraber and Mahley, 1978). Rat HDL and probably the HDL of LCAT-deficient subjects contain a minor constituent apoA-IV (MW ~ 46,000; Swaney *et al.*, 1977; Utermann *et al.*, 1974).

Although there are reports that the ratio of apoA-I to apoA-II is identical in HDL₂ and HDL₃ (Friedberg and Reynolds, 1976) or higher in HDL₂ (Albers and Aladjem, 1971), the majority of workers have found a higher ratio in HDL₂ (Kostner *et al.*, 1974; Kostner and Alaupovic, 1972; Bornt

and Aladjem, 1971). Cheung and Albers (1977) have reported an apoA-I/apoA-II weight ratio of 5.1 (men) or 6.1 (women) in HDL₂ and 3.7 (men) or 3.8 (women) in HDL₃. An increase in the ratio of HDL₂/HDL₃, such as occurs in women compared to men (Cheung and Albers, 1977) or in long-distance runners (Krauss *et al.*, 1977), results in an increase in the apoA-I/apoA-II ratio in plasma.

The Schlieren pattern of HDL in the analytic ultracentrifuge shows two major peaks. The F_{1,2}⁰ 3.5–9 subclass approximates HDL₂ and the F_{1,2}⁰ 0–3.5 subclass HDL₃. Anderson *et al.* (1977) have recently identified three subclasses of HDL by equilibrium density ultracentrifugation, of densities 1.063–1.10 g/ml (108–120 Å), 1.100–1.125 (97–107 Å), and 1.125–1.063 (85–96 Å). Having developed a method for resolving HDL Schlieren patterns into contributions from these three different components, they have estimated their relative contributions to plasma HDL in a normal population sample (Anderson *et al.*, 1978). These studies show that HDL₃ levels in plasma are relatively constant [158 ± 30 mg/dl (SD)]. The density 1.100–1.125 (HDL_{2a}) and 1.063–1.100 (HDL_{2b}) are highly correlated with plasma HDL levels. Individuals with HDL levels less than 100 mg/dl have mainly HDL₃; increases in total HDL up to 200 mg/dl are due to increases in HDL_{2a}; increases up to 475 mg/dl are due to HDL_{2a} and HDL_{2b}; and with HDL levels in excess of 475 mg/dl there are additional faster floating components in the Schlieren pattern. Thus, increases in plasma HDL levels are due to the incremental build-up of subclasses of increasing Sf values, i.e., larger HDLs.

Miniature swine fed diets enriched in saturated fat and cholesterol develop hypercholesterolemia and accelerated atherosclerosis. A lipoprotein called HDL_c (cholesterol-induced) appears in the plasma in appreciable concentrations (Mahley *et al.*, 1975). HDL_c is cholesterol ester-rich, has electrophoretic α -2 mobility, a size intermediate between LDL and HDL₂, and an apoprotein content including the arginine-rich (apoE) and A-I apoproteins.

HDL_c is also induced in other species such as dogs (Mahley and Weisgraber, 1974; Mahley *et al.*, 1974), man (Mahley *et al.*, 1978), and rats (Mahley and Holcombe, 1977) by cholesterol feeding. The composition and size of HDL_c from swine are shown in Table 1 (Mahley *et al.*, 1975; Tall *et al.*, 1977a; Atkinson *et al.*, 1978).

B. APOLIPOPROTEIN STRUCTURE

A major advance in our knowledge of lipoprotein structure has resulted from the purification and amino acid sequencing of the serum apolipoproteins. ApoA-I consists of a single chain of about 245 residues (Baker *et al.*,

Table I
COMPOSITION AND SIZE OF HDL_c FRACTIONS

| | 1.02-1.04 | 1.04-1.06 | 1.06-1.09 |
|---------------------------|--|----------------------|----------------------|
| Protein | 15.8 | 20.3 | 25.7 |
| Phospholipid | 17.5 | 29.3 | 32.5 |
| Cholesteryl ester | 56.3 | 42.5 | 35.0 |
| Cholesterol | 9.9 | 7.5 | 6.2 |
| Triglyceride | 0.5 | 0.5 | 0.6 |
| Major apoprotein | apoE | apoE, apoA-I | apoA-I |
| Diameter ^a (Å) | 175-225 ^a 180 ^b | 150-200 ^a | 125-185 ^a |

^a From negative stain electron microscopy.

^b From analysis of X-ray scattering.

1974, 1975; Brewer *et al.*, 1978). ApoA-II has two identical chains linked by a disulfide bond at residue 6 (Brewer *et al.*, 1972). The sequences of the smaller C-apolipoproteins are also known. ApoC-I has 57 residues (Jackson *et al.*, 1974a,b), apoC-II, 78 residues (Jackson *et al.*, 1977), and apoC-III, 79 residues (Brewer *et al.*, 1974). Based on CPK space-filling models of the amino acid-sequenced water-soluble apolipoproteins, Segrest and co-workers (Segrest *et al.*, 1974; Segrest, 1977; Segrest and Feldmann, 1977) speculated that the apoproteins probably contain segments of helix in which one face of the helix contains predominantly hydrophilic amino acid residues, while the other face contains a strip of hydrophobic amino acids. They suggested that in lipoproteins the hydrophobic strip might interact with the fatty acyl chains of the phospholipids, and that there might be ionic interactions between the polar helical face and the zwitterionic phosphorylcholine moiety of the lecithin. The term "amphipathic helix" was coined to describe these lipid-binding helical segments. Experimental validation of this hypothesis has resulted from the synthesis of peptide fragments which have amphipathic polar and apolar faces and which also display the capacity to form lipoprotein complexes with lecithins (Sparrow *et al.*, 1977). Investigations of lipoprotein recombinants using nuclear magnetic resonance spectroscopy (Assmann *et al.*, 1974; Assmann and Brewer, 1974; Stoffel *et al.*, 1974; Finer *et al.*, 1975; Stoffel and Darr, 1976) and chemical cross-linking (Stoffel *et al.*, 1977) have shown the importance of hydrophobic interactions in the stabilization of the complexes, while there is little evidence showing ionic interactions. In fact, if the putative ionic interaction were of primary importance then one might expect marked loss of apoproteins from the lipoproteins during routine isolation in high salt concentrations (Havel *et al.*, 1955).

McLachlan (1977) has reported a high frequency of homology of amino acids between segments (11 or 22 amino acids long) within the apoA-I sequence, suggesting that the sequence may have evolved by internal gene duplication. Such homology may also reflect convergent evolution of sequences of similar amphipathic character.

Studies of apoprotein conformation in solution have provided insight into apoprotein structure (Scanu, 1969). Jonas (1973) reported that bovine apoHDL has a high degree of exposure of tyrosine and tryptophan residues to the aqueous solvent, suggesting that the apoprotein has an extended conformation. By contrast, in intact HDL tyrosine and tryptophan residues were less exposed to the solvent. Gwynne *et al.* (1974, 1975a,b) showed that apoA-I and apoA-II are denatured in low concentrations of guanidinium hydrochloride. Employing scanning calorimetry and ultraviolet difference spectroscopy, Tall *et al.* (1975, 1976) studied the thermal and urea-induced denaturation of apoA-I and showed that free energy difference (ΔG) between the folded and unfolded states of the apoprotein was small (2.4 kcal/mol at 37°C), compared to other small globular proteins like myoglobin or ribonuclease (~ 10 kcal/mol) (Privalov and Khechinashvili, 1974). Reynolds (1976) confirmed that there was little free energy difference between the native and denatured (completely unfolded) forms of apoA-I or apoA-II in guanidinium HCl, in contrast to intrinsic membrane proteins which are resistant to complete unfolding by the same denaturant. These properties probably account for the cooperative binding of detergents by apoA-I at very low detergent concentrations (Reynolds and Simon, 1974). These findings indicate that the apolipoproteins have a loosely folded conformation in solution with a high degree of exposure of hydrophobic amino acid residues to the solvent. Such conformational properties are important in two respects. First, they probably provide hydrophobic sites for protein-protein self-association known to occur in solutions of isolated apoproteins (v.i.). Second, they probably determine the lipid-binding capacity of the apolipoproteins, by providing ready access of lipid molecules to manifold hydrophobic sites on or within the protein globule.

There is abundant evidence that apoA-I, apoA-II and, apoC-I undergo self-association in solution (e.g., Vitello and Scanu, 1976; Stone and Reynolds, 1975; Osborne *et al.*, 1976, 1977; Gwynne *et al.*, 1975b). Stone and Reynolds (1975) and Jonas and Krajinovich (1977) have presented evidence that self-association does not greatly influence lipid binding. Ritter and Scanu (1977) have shown that monomeric apoA-I forms complexes more readily than multimeric A-I when sonicated with total HDL lipid. Major differences in apoA-I and apoA-II lipid binding have been reported (Assmann and Brewer, 1974; Middelhoff *et al.*, 1976) probably due to differences in their kinetics of interaction with lipid, or to apoprotein self-

association. The earlier reports that apoA-I does not form recombinants with phosphatidylcholines have not been borne out in most subsequent studies (Tall *et al.*, 1975, 1977c; Ritter and Scanu, 1977). No study of the effect of apoprotein self-association on recombination with lipid has adequately differentiated between kinetic effects as opposed to behavior at equilibrium.

Recently Swaney and O'Brien (1978) have studied the self-association of apoA-I and apoA-II, using the cross-linking reagent dimethylsuberimide. At low concentration apoA-I was monomeric but associated to tetramers and pentamers at concentrations of 0.5 mg/ml or higher. For apoA-II the main oligomeric form was the dimer. These results were in general agreement with the hydrodynamic studies. Interestingly, phospholipid-apoA-II recombinants contained trimers upon cross-linking.

C. RECOMBINANTS OF APOLIPOPROTEINS AND LIPIDS

Hirz and Scanu (1970) showed that ultrasonically dispersed HDL lipids (phospholipids and cholesteryl esters) could be recombined with apoHDL to produce a particle resembling native HDL. In the absence of phospholipid, ultrasonically treated cholesterol and cholesteryl ester did not recombine with apoHDL. ApoA-I can be recombined with myelin figures of phospholipid (multilamellar liposomes) by simple incubation (Tall *et al.*, 1975), or by cosonication, both methods producing an HDL-phospholipid particle of identical composition (Ritter and Scanu, 1977). However, recombination of whole HDL lipids (including phospholipid, cholesterol, cholesteryl ester, and triglyceride) with apoA-I required cosonication, producing an HDL particle of radius 31 Å (two molecules apoA-I per particle) or 39 Å (three molecules of apoA-I per particle). The circular dichroism spectra of HDL apoproteins show an increased helical content of the apoproteins upon recombination with phospholipid (Lux *et al.*, 1972a,b; Jackson *et al.*, 1973), indicating conformational stabilization of the apoprotein in the lipoprotein complex. Studies of HDL recombinants prepared from egg yolk lecithin vesicles and apoC-I show that the increased apoprotein helical content is associated with a movement of tryptophan residues to a more hydrophobic environment, as shown by a 5-nm blue shift in the fluorescence maximum (Jackson *et al.*, 1974b). Differential scanning calorimetry of HDL recombinants prepared from dimyristoyl or dipalmitoyl lecithin and apoA-I showed an increased temperature and enthalpy of denaturation of apoprotein in the lipoprotein complex (Tall *et al.*, 1975, 1977c). The lipoprotein denaturation was a two-state process and gave a calculated free energy of association of DML and apoA-I of 10.5 kcal/mol (37°C).

Under most conditions apoA-I and apoA-II form recombinants with




FIG 1. Schematic representation of an apoHDL/DML complex containing about 60% DML; (top) cross-section with three dimensional view; and (bottom) top view. The complex consists of a phospholipid bilayer disc with apoprotein α -helices forming an annulus around the edge of the disc. The hydrophobic surface of the apoprotein amphipathic helices (dotted hatching) contact the phospholipid hydrocarbon chains. D represents the total diameter of discs; h , the length of apoprotein helix in contact with phospholipid; and t , the width of the apoprotein helix. In the top view the outer layer (apoprotein) interacts with a boundary zone of phospholipid one to two molecules thick (light hatching), while the phospholipid molecules in the center (dark hatching) can undergo gel-liquid crystalline transitions. From Tall *et al.* (1977c).

lecithin alone which have the structure of a discoidal phospholipid-bilayer (Fig. 1). Under certain conditions, to be discussed, the product retains the structure of a unilamellar phospholipid vesicle. Forte *et al.* (1971a, b) first demonstrated that the high-density lipoprotein recombinant resulting from the cosonication of egg yolk lecithin and apoA-I had the morphology of a lipid bilayer disc, $150\text{--}200 \times 45\text{Å}$, when viewed by negative stain electron microscopy. Discoidal or vesicular lipoproteins will stack in rouleaux when dehydrated and examined by electron microscopy. Atkinson *et al.* (1976), studying the complexes of dimyristoyl lecithin with bovine apoHDL